Director Lynne Parshall trims Cytokinetics (CYTK) stake in sale

Rhea-AI Filing Summary

Cytokinetics Inc director Lynne Parshall reported an open-market sale of common stock. On March 2, 2026, she sold 5,000 shares at an average price of $61.21 per share. After this transaction, she directly owns 17,933 shares of Cytokinetics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARSHALL B LYNNE

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S		5,000	D	$61.21	17,933	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Ms. Parshall	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CYTOKINETICS (CYTK) report in this Form 4?

CYTOKINETICS reported that director Lynne Parshall sold 5,000 shares of common stock in an open-market transaction at an average price of $61.21 per share, and now directly holds 17,933 shares of Cytokinetics common stock following this sale.

How many CYTOKINETICS (CYTK) shares did Lynne Parshall sell and at what price?

Director Lynne Parshall sold 5,000 shares of CYTOKINETICS common stock. The sale was executed as an open-market transaction at an average price of $61.21 per share, as disclosed in the Form 4 insider trading report filed for this transaction.

How many CYTOKINETICS (CYTK) shares does Lynne Parshall own after the reported sale?

After selling 5,000 shares, director Lynne Parshall directly owns 17,933 shares of CYTOKINETICS common stock. This remaining ownership amount is reported in the Form 4 as her total direct holdings following the open-market sale on March 2, 2026.

Was the CYTOKINETICS (CYTK) insider trade a buy or sell transaction?

The transaction was a sell. The Form 4 classifies it with code “S,” indicating a sale in an open-market or private transaction, and shows Lynne Parshall disposing of 5,000 shares of CYTOKINETICS common stock at an average price of $61.21 per share.

Does the CYTOKINETICS (CYTK) Form 4 indicate direct or indirect ownership?

The Form 4 identifies the 5,000-share sale and the remaining 17,933 shares as directly held by Lynne Parshall. The ownership code is listed as “D,” meaning direct ownership, with no additional nature-of-ownership footnote describing an indirect holding entity.